Patent · US Active

Aspartyl-tRNA synthetases

US9816084B2 · kind B2 · utility

0Cited by

75References

24Claims

0Family size

Assignee

aTyr Pharma, Inc. · US

Inventors

Ying Buechler · Carlsbad, US
Chi-Fang Wu · San Diego, US
Ryan Andrew Adams · San Diego, US
Kristi Helen Piehl · San Diego, US
Jeffrey Greve · Branford, US
John D. Mendlein · Encinitas, US

Key dates

Filing date	Dec 6, 2012
Grant date	Nov 14, 2017
Priority date	—
Expiry date	Sep 28, 2033

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.